000300178 001__ 300178
000300178 005__ 20250406015910.0
000300178 0247_ $$2doi$$a10.1136/bmjmed-2024-000909
000300178 0247_ $$2pmid$$apmid:40151205
000300178 0247_ $$2pmc$$apmc:PMC11948348
000300178 0247_ $$2altmetric$$aaltmetric:175486109
000300178 037__ $$aDKFZ-2025-00655
000300178 041__ $$aEnglish
000300178 082__ $$a610
000300178 1001_ $$aDavila-Batista, Veronica$$b0
000300178 245__ $$aAssociations between cardiometabolic comorbidities and mortality in adults with cancer: multinational cohort study.
000300178 260__ $$a[London]$$bBMJ Publishing Group Ltd.$$c2025
000300178 3367_ $$2DRIVER$$aarticle
000300178 3367_ $$2DataCite$$aOutput Types/Journal article
000300178 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1743423055_2196
000300178 3367_ $$2BibTeX$$aARTICLE
000300178 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300178 3367_ $$00$$2EndNote$$aJournal Article
000300178 520__ $$aTo examine separate and joint associations between pre-existing cardiometabolic comorbidities and all cause and cause specific mortality in adults with cancer.Multinational cohort study.Seven European countries from the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 1 January 1992 to 31 December 2013.26 987 participants (54% women) who developed a first primary cancer. 2113 had a history of type 2 diabetes, 1529 had a history of cardiovascular disease, and 531 had a history of both, at the time of diagnosis of cancer.Hazard ratios (95% confidence intervals, CIs) for associations between pre-existing cardiometabolic comorbidities and all cause and cause specific mortality in adults with cancer, estimated with multivariable Cox regression models. Associations were also estimated by groups of five year relative survival of cancer (survival ≤40%, 40-80%, and ≥80%) according to Surveillance, Epidemiology, and End Results (SEER) statistics, and for the most common site specific cancers.At the time of diagnosis of cancer, 84.5% (n=22 814) of participants had no history of a cardiometabolic disease, 7.8% (n=2113) had a history of type 2 diabetes, 5.7% (n=1529) had a history of cardiovascular disease, and 2.0% (n=531) had a history of both cardiovascular disease and type 2 diabetes. 12 782 deaths (10 492 cancer deaths) occurred over a mean follow-up period of 7.2 years. After multivariable adjustments, pre-existing comorbidities were positively associated with all cause mortality, with hazard ratios 1.25 (95% CI 1.17 to 1.34), 1.30 (1.21 to 1.39), and 1.60 (1.42 to 1.80) for participants with type 2 diabetes, cardiovascular disease, or both, respectively, compared with participants with no cardiometabolic comorbidity. Corresponding hazard ratios for cancer specific mortality were 1.13 (95% CI 1.05 to 1.22), 1.13 (1.04 to 1.23), and 1.33 (1.16 to 1.53), respectively. Associations for all cause mortality were stronger among participants with cancers with a five year relative survival ≥80%. In a subsample, duration of type 2 diabetes (Pinteraction=0.73) or cardiovascular disease (Pinteraction=0.24), categorised as <5 years or ≥5 years, did not modify associations between these comorbidities and all cause mortality.In this study, cardiovascular disease or type 2 diabetes, or a combination of both, before a diagnosis of cancer, was associated with increased mortality (all cause mortality, and cancer and cardiovascular disease specific mortality). These findings support a direct role of cardiometabolic comorbidities on the prognosis of cancer.
000300178 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000300178 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300178 650_7 $$2Other$$aDiabetes mellitus
000300178 650_7 $$2Other$$aEpidemiology
000300178 650_7 $$2Other$$aMyocardial infarction
000300178 650_7 $$2Other$$aStroke
000300178 7001_ $$aViallon, Vivian$$b1
000300178 7001_ $$aFontvieille, Emma$$b2
000300178 7001_ $$aJansana, Anna$$b3
000300178 7001_ $$aKohls, Mirjam$$b4
000300178 7001_ $$aBondonno, Nicola P$$b5
000300178 7001_ $$aTjønneland, Anne$$b6
000300178 7001_ $$aDahm, Christina C$$b7
000300178 7001_ $$aAntoniussen, Christian S$$b8
000300178 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b9$$udkfz
000300178 7001_ $$aBajrachaya, Rashmita$$b10
000300178 7001_ $$00000-0002-0830-5277$$aSchulze, Matthias B$$b11
000300178 7001_ $$aAgnoli, Claudia$$b12
000300178 7001_ $$aRicceri, Fulvio$$b13
000300178 7001_ $$aPanico, Salvatore$$b14
000300178 7001_ $$aZamora-Ros, Raul$$b15
000300178 7001_ $$aRodriguez-Barranco, Miguel$$b16
000300178 7001_ $$aAmiano, Pilar$$b17
000300178 7001_ $$aChirlaque, Maria-Dolores$$b18
000300178 7001_ $$aMoreno-Iribas, Conchi$$b19
000300178 7001_ $$aPapier, Keren$$b20
000300178 7001_ $$aTsilidis, Konstantinos K$$b21
000300178 7001_ $$00000-0002-4533-1722$$aAune, Dagfinn$$b22
000300178 7001_ $$aGunter, Marc J$$b23
000300178 7001_ $$aWeiderpass, Elisabete$$b24
000300178 7001_ $$aJenab, Mazda$$b25
000300178 7001_ $$aFerrari, Pietro$$b26
000300178 7001_ $$aFreisling, Heinz$$b27
000300178 773__ $$0PERI:(DE-600)3128592-2$$a10.1136/bmjmed-2024-000909$$gVol. 4, no. 1, p. e000909 -$$n1$$pe000909$$tBMJ medicine$$v4$$x2754-0413$$y2025
000300178 909CO $$ooai:inrepo02.dkfz.de:300178$$pVDB
000300178 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000300178 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000300178 9141_ $$y2025
000300178 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-30
000300178 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-24T13:07:12Z
000300178 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-24T13:07:12Z
000300178 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2024-01-24T13:07:12Z
000300178 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-30
000300178 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-30
000300178 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-30
000300178 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-30
000300178 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-30
000300178 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000300178 980__ $$ajournal
000300178 980__ $$aVDB
000300178 980__ $$aI:(DE-He78)C020-20160331
000300178 980__ $$aUNRESTRICTED